Consensus CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.13 ^USD	+13.00%		+34.33%	-25.65%

May. 02	CUREVAC : A missed opportunity
Apr. 26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

Evolution of the average Target Price on CureVac N.V.

Price target over the last 5 years

History of analyst recommendation changes

ac0b86cba33518d27563a8.tXeSgIrLu-ZWqzJhL4XvJxYH5EPXIhhYvxtdEyYWGEY.7U_K0ee9zqMnw0hYZ_apdFk-0ACmRyky710rPm9RVCXFRf7S8JrrgXucVQ~50c424ecaa8ccc99ce4898f602e1d1ba

Analyst Recommendations on CureVac N.V.

CUREVAC : A missed opportunity	May. 02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	Apr. 26	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	Apr. 25	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	Dec. 22	MT
CUREVAC : An untrimmed pipeline becomes costly	Nov. 29
CUREVAC : Unchanged cash drain	Nov. 28
CUREVAC : A missed opportunity	23-08-21
CUREVAC : Higher losses expected in future	23-07-25
CUREVAC : Some glimpse of positive pipeline developments	23-06-21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	23-06-08	MT
CUREVAC : Runway prolonged	23-05-30
CUREVAC : One big point despite many misses	23-05-02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	23-04-26	MT
CUREVAC : Everything hangs on the decision of the new CEO	23-03-16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	23-01-19	MT
CUREVAC : UBS raises its recommendation to Buy	23-01-19	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Jefferies Upgrades CureVac to Buy From Hold	23-01-09	MT
CUREVAC : Berenberg reaffirms its Buy rating	23-01-06	ZD
UBS Initiates Coverage on CureVac With Neutral Rating, $8 Price Target	22-12-20	MT
JMP Securities Adjusts Price Target on CureVac to $34 From $37, Maintains Market Outperform Rating	22-11-17	MT
Berenberg Bank Adjusts CureVac Price Target to $22 From $45, Maintains Buy Rating	22-11-17	MT
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
Berenberg US CEO Conference	22-11-01	FA
Berenberg/Goldman Sachs German Corporate Conference	22-09-19	FA

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.906 EUR

Average target price

9.189 EUR

Spread / Average Target

+216.24%

High Price Target

16.84 EUR

Spread / Highest target

+479.71%

Low Price Target

2.433 EUR

Spread / Lowest Target

-16.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CureVac N.V.

alphavalue	Martin Schnee
UBS
Leerink Partners
Kempen
SVB Securities LLC
JMP Securities
Jefferies & Co.
BERENBERG	Zhiqiang Shu
Berenberg Bank
BofA Securities
Deutsche Bank Securities
Guggenheim

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar